Interaction of ductal obstruction and glandular dropout in the pathogenesis of meibomian gland dysfunction

来源期刊： Eye Science | 2024年9月第1卷第3期： 190-205 发布时间：2024-09-10 收稿时间：2024/10/21 11:31:38 阅读量：427

作者：: 刘仁,

薛建文,

韩佳栩,

李晶,

陈子沿,

梁凌毅,

关键词：: Meibomian gland dysfunction Hyperkeratinization Inflammation Progenitor PPARγ; Meibomian gland dysfunction Hyperkeratinization Inflammation Progenitor PPARγ

DOI：: 10.12419/es24070204

Received date：: 2024-07-02
Accepted date：: 2024-08-14
Published online：: 2024-09-10

Meibomian gland dysfunction (MGD) manifests through two main clinical presentations, characterized by the meibomian gland (MG) ductal obstruction or acinar dropout. While previous research has predominantly associated MGD pathogenesis with hyperkeratinization-related MG ductal obstruction and subsequent acinar atrophy, recent cases have shown significant functional acinar loss in the absence of apparent ductal keratinization or blockage. The deterioration of either MG obstruction or dropout exacerbates the condition of the other, suggesting an independent yet interconnected relationship that perpetuates the vicious cycle of MGD. Understanding the distinct pathological features of MG obstruction and dropout is crucial for delineating their etiology and identifying targeted therapeutic strategies. This review explores the nuanced interrelations of MG obstruction and dropout, elucidating potential pathological mechanisms to establish a foundation for early MGD diagnosis and intervention.

HIGHTLIGHTS

1.Critical Discoveries and Outcomes

This review synthesizes evidence from population studies and experimental research to elucidate the interaction of meibomian gland obstruction and dropout in the pathogenesis of meibomian gland dysfunction.

2.Methodological Innovations

This review delves into the intricate interaction between ductal obstruction and glandular dropout within the meibomian gland, based on the structural and functional distinction of ductal and acinar epithelia.

3. Prospective Applications and Future Directions

The potential pathological mechanisms summarized in this study offer valuable insights that could inform the early diagnosis and intervention of meibomian gland dysfunction.

1. Introduction

As the largest sebaceous gland in humans, the MG is situated in the upper and lower eyelids, comprising acinar and ductal components. ^[1] The MG produces meibum via holocrine secretion, whereby lipid-rich mature differentiated acinar cells (meibocytes) migrate, degenerate, and disintegrate within the terminal duct to release meibum, formating the tear film lipid layer (TFLL), thereby producing smooth optical surface and reducing tear evaporative rate^[2]. Meibomian gland dysfunction (MGD) is characterized by ductal obstruction or glandular dropout accompanied by qualitative or quantitative abnormalities in meibum ^[3]. Ductal obstruction in MG is characterized by the blockage of the terminal duct due to condensed meibum of inferior quality and expressibility ^[4]. Glandular dropout involves functional acinar loss ^[5], using in vivo confocal microscopy (IVCM) can detect a significant reduction in MG acinar unit diameters and density ^[6]. MGD destroys tear film structure and increases tearing osmolarity, contributing to the occurrence of evaporative dry eye disease (EDED). The global prevalence of MGD ranged from 30.5%-68% ^[7-8], which is especially common among the elderly and has become a very common eye disease affecting life quality worldwide ^[9-10].

The pathogenesis of MGD remains elusive. Previous hypothesis supported that the initial step of MGD involved gland obstruction due to hyperkeratinization of the ductal epithelium, leading to duct dilation and chronic intraglandular high pressure, ultimately causing secondary glandular dropout ^{[3, 11]}. However, this theory failed to fully account for certain observations in MGD patients, such as those with age-related MGD, who displayed significant glandular dropout with minimal evidence of obstruction ^[12]. It was known that the risk factors for MGD related to meibum metabolism disorder or damage to the MG ductal epithelial cells include chronic inflammatory infiltration and fluctuations in sex hormones ^[13-15]. These factors can lead to ducts hyperkeratinization and imbalance in meibum lipid composition, resulting in intraductal meibum stagnation, thereby inducing MG blockage, such prolonged blockage further increased intraductal pressure, ultimately induced functional acinar atrophy^[16-17]. However, under the influence of aging and benzalkonium (BAK) chloride exposure ^[18-19], significant loss of progenitor cells and acinar cells can occur independently without apparent MG obstruction. Characterizing MG dropout solely as a progressive result of MG ductal obstruction overlooks the early diagnostic potential of glandular dropout, which exhibits high sensitivity (96.7%) and specificity (85%) in identifying MGD ^[20]. Notably, the loss of MG acini also affected meibocyte differentiation and meibum metabolism, increasing the risk of MG obstruction ^[21-22]. These findings indicate that glandular dropout and ductal obstruction of MG occur relatively independently and together contribute to a vicious cycle in the development of MGD.

In this review, based on the latest experimental evidence, we summarizing the pathological mechanisms about different clinical characteristics of MGD, attempting to elucidate the interaction between MG ductal obstruction and glandular dropout, aiming to better guide clinicians to diagnose and treat MGD.

2. How do risk factors determine ductal obstruction?

2.1 Chronic inflammation

IVCM detection found that the number of inflammatory cells within the MG glandular duct among MGD patients was twice that of healthy control^[23]. Immunofluorescent staining of human eyelid specimens also detected CD45⁺ leukocyte infiltrated around MG was significantly associated with MG obstruction (r =0.414, P <0.05) ^[19]. The recruitment of Th17-mediated neutrophils orchestrated by the ocular immune system within the MG microenvironment may contribute to the pathogenesis of MG ductal alterations. Evidence from animal studies confirmed this theory, inflammatory model of allergic eye disease in mice showed obvious obstructive MG, central duct dilatation, and epithelium thickening, which was significantly associated with periglandular infiltration of polymorphonuclear neutrophils ^[24]. Besides, inflammatory stress activated by NF-κB made apolipoprotein E (APOE) deficient mice showed dilated MG duct and MG orifice plugging with increased keratinization and neutrophil infiltration ^[25]. Results from the organotypic culture of MG first revealed the potential mechanism, 50ng/ml neutrophil chemoattractant IL-1β exposure caused overexpression of Keratin 1 in MG ducts ^[13], indicating that keratinization of MG duct caused by chronically inflammatory stimulation seems to be the origination of MG obstruction.

2.2 Sex hormones fluctuation

Estrogen fluctuation is a risk factor for inducing obstructive MGD, whereas androgen shows protective effects. Both androgen receptor and estrogen receptor have been reported to express in human MG ^[26], and common signature genes of meibum metabolisms showed a similar fashion of male and female populations ^[27]. However, androgen supplementation enhances the expression of MG keratinization inhibition and meibum synthesis associated genes, such as sterol regulatory element binding proteins 1 and 2 ^[28-29]. Compared to normal people, chronic antiandrogen medication users and complete androgen insensitivity syndrome patients showed a higher incidence of MGD with severe MG obstruction, decreased meibum quality ^[14], and an over two fold increased of dry eye symptoms including the sensations of dryness, pain, and light sensitivity ^[17]. On the contrast, extra estrogen upregulated the expression of meibum decomposition and MG keratinization associated genes ^[30]. Higher serum estrogen level in postmenopausal women characterized as a significant predictor of worse MG obstruction ^[15].

Suzuki divided the menstrual cycle into six phases (phase I-VI), the straight-chain saturated fatty acids (SFA) significantly increased and the ratio of mono-unsaturated fatty acids (UFA) significantly decreased in phase II and returned to normal levels in phase III-V ^[31]. Meibum SFA/UFA of the androgen deficiency patients also had significant changes, showing as imbalanced content of cholesterol esters and wax esters ^[14]. It has known that knockout of the rate-limiting enzyme stearoyl-CoA desaturase 1 for the monounsaturated fatty acids synthesis ^[32] and the elongase of very long chain fatty acid (ELOVL) for very-long-chain fatty acids synthesis ^[33], all significantly altered SFA/UFA ratio in meibum, which associated with MG ductal epithelium hyperplasia, central ducts narrowing, and obstruction. These indicate that sex hormones fluctuation may induce MG obstruction by altering the proportion of meibum SFA and UFA ^[31]. Changes of SFA/UFA ration would enhance the lipid-lipid interaction strength, which makes meibum exhibit higher phase transition temperature and unsaturation, causing it transited from a relatively disordered liquid state to a more ordered solid state ^[34-35]. Solid meibum often secrets stagnation, gradually accumulates in the glandular duct causing MG ductal keratinization and obstruction ^{[3, 25]}. Moreover, solid meibum has a reduced fluidity makes it more difficult to spread on the tear film (TF), formatting inefficient and thinner TFFL ^[35], inducing a desiccative and hypertonic ocular environment, which further leads to meibocyte differentiation and meibum metabolisms abnormalities ^[21].

Recently, multiple targets were demonstrated to be involved in the meibum metabolisms, the most important one is peroxisome proliferator-activated receptor gamma (PPARγ). PPARγ agonist rosiglitazone upregulated meibocyte differentiation-related proteins, like adipophilin (ADFP), elongation of ELOVL4, and fatty acid binding protein 4 (FABP4) ^[36]. The positive effects of PPARγ on MG involved the regulation of Wnt and Hedgehog pathways ^[36-37], and inhibiting NF-κB pathway to correct the metabolic disorder of meibum lipids and MG obstruction in APOE deficient mice ^[25]. Activated NOTCH signaling suppressed Human meibomian gland epithelial cells (HMGECs) proliferation but promote its meibum synthesis ^[38]. In addition, 1nM insulin-like growth factor 1 (IGF-1) treatment activated PI3K/AKT and forkhead box O1 (FoxO1) pathways, simultaneously facilitated meibum production and proliferation of HMGECs^[39].

2.3 Incomplete blinking

Ruled by cranial nerve seven (CN VII), the human blinking process identified as having four phases: downstroke, turning point, upstroke, and the interblink interval ^[40]. During the phase of downstroke to upstroke, blinking facilitates the spread and distribution of TF, and the formation of TFLL by continuous meibum secretion regulated by synchronized eyelid muscular actions ^[3], while the evaporation and break up of TF arise in the interblink interval. Abnormal blinking is characterized as incomplete blinking (IB) or higher partial blinking rate (PBR) which is associated with MG obstruction, worse meibum quality, TBUT, and OSDI scores ^[41]. A week blinking training could significantly improve the MGD-related symptoms of IB populations ^[42]. A plausible mechanism is that IB inhibits the squeezing power of orbicularis muscle and Riolan muscle, leading to meibum excretion reduction and stasis in the glandular ducts which finally caused MG obstruction ^[3]. IB also arises TFLL unevenly distributed ^[41], causing increased tear evaporation rate and a desiccative ocular environment ^[43], which in turn leads to MG differentiation and meibum production abnormalities, exacerbating MG obstruction ^[21]. Patients with secondary IB diseases, like CN VII palsy, thyroid eye disease (TED), and reduced corneal sensitivity caused by diabetic peripheral neuropathy also showed similar obstructive MGD features ^[44-46].

2.4 Racial difference

The difference between the human race is quite an interesting risk factor of MGD. Compared to Western countries, age-matched people in Asian countries exhibit a higher incidence of MGD ^{[7, 47]}. After excluding the difference of diagnostic criteria and environment, this phenomenon remained the same that adult Asian descendants appeared poorer meibum quality, OSDI scores, TF stability, TFLL structure, and tear osmolarity ^{[7, 47- 48]}.

One of the possible explanations is the change of eyelid tension determined by different anatomy ^[49-50]. In the Caucasian eyelid, levator aponeurosis penetrates the orbital septum at a higher location which induces the upper palpebral crease ^[49-50]. On the contrary, the lower penetrated position in Asian eyelid making the tension of eyelid increased ^[49]. The larger exposed ocular surface area makes both Asian pediatric and young populations showed higher PBR and more susceptible to suffer MG obstruction ^[51-52].

Another interpretation is the different consumption of supplements between Asian and Caucasian populations, such as fish oil, a kind of supplement contains abundant omega-3 (ω-3) fatty acids ^[53]. Fish oil and ω-3 are the third most popular dietary supplementations among the Caucasian population, with a frequency of 9.8%-12% ^[53-54], while that in the Asian population is no more than 5% ^[55]. It has been demonstrated that reasonable ω-3 supplementation decreased the prevalence of MGD and improved meibum quality in postmenopausal women^[56]. ω-3 regulated the content of SFA ^[57] in meibum by altering the differentiation of HMGECs ^[58]. Besides, a random clinical trial demonstrated that 1.5g/d ω-3 intake lowered MGD-linked lid inflammation ^[59]. Through increasing the expression of resolvin D1 and cutting the production of cyclooxygenase-2, ω-3 exerted anti-inflammatory effects to inhibit cytokine activity of HMGECs ^[60]. These indicate that ω-3 exerts meibum-regulation and anti-inflammatory effects to refrain MG ductal hyperkeratinization and subsequent obstruction.

2.5 Contact lens

Whatever soft or rigid lens, daily contact lens (CL) wearing is recognized as a risk factor of MGD ^[61-62]. Daily CL wearers showed obvious MG obstruction with meibum abnormalities, OSDI and CFS were also significantly higher ^[62]. Two explanations may help to describe this phenomenon. Mechanical trauma from the CL induced desquamated ductal epithelial cells accumulated in the opening end of the duct ^[63], the continuous secretion of meibum eventually blocked MG ^{[61-62, 64]}. Besides, CL wearing also increased the expression level of IL-17A, TNF-α, and IL-6 in tears ^[65-66], which made MG face the risk of ductal hyperkeratinization and blockage.

The development of MGD in daily CL wearers possesses obvious time regularity. The damage of CL to MG tended to concentrate on the first 2-3 years and remain stable for more than 7 years ^[67-68]. Compared to healthy control or long-term CL wearers (≥3 years), the related MG parameters were significantly worse in short experience (＜3 years) ^[67-68]. This may relate to the constant inflammatory stimulation at the early stage, for even after wearing CL for several hours the expression of tear IL-17A tripled ^[65]. Besides, the tearing IL-6 level of CL wearers was significantly upregulated and became to normal levels after 6 days of cessation but returned to the original levels within 24h after re-wearing CL^[66]. Therefore, early treatment is necessary for better control of MGD progression in CL wearers, however, why CL-related MGD lacks aggravation in the later period is still inconclusive, prospective longitudinal studies needed to be carried to obtain a reasonable explanation.

2.6 Demodex infestation

The found of Demodex in the obstructive and dilatated ducts with abnormal keratinization of MGD patients suggested that ocular Demodex infestation may be a potential risk factor of MG obstruction ^[69]. Demodex folliculorum (D.f) and Demodex brevis (D.b) are the only two types of mites that parasitic to humans^[70]. Clinical observations found that patients with ocular Demodex infestation showed higher incidence and degree of MGD than healthy populations ^[71]. MG secretions and eyelashes from ocular Demodex infection positive patients showed complicated bacteria profiles (higher proportion of P. acnes, S.aureus, Staphylococcus, and Streptococci) ^[72-73]. Demodex’s intestine also harboured Bacillus oleronius which could trigger a host immune response via producing pro-inflammatory proteins ^[74]. This indicated that Demodex may act as the vehicle of bacterias and induce host inflammatory response to increase the risk of MG obstruction ^[73-74]. Our former study also found almost 90% of young ocular demodicosis patients possessed MGD, which was significantly associated with D.b infestation rather than D.f ^[71]. Besides, D.b infestation was associated with worse meibum quality ^[75]. This was consistent with the fact that D.b tends to the resident in MG ^[76], while D.f prefers parasitizing in the lash follicle ^[77], the mechanical irritation of D.b may lead to reactional MG epithelial hyperplasia and glandular obstruction ^[77]. The chitinous exoskeleton of D.b may also act as a foreign body and cause granulomatous reactions ^[76]. Therefore, a higher Demodex infection rate, particularly D.b, may one of the risk factors of MG obstruction.

3. How do risk factors determine glandular dropout?

3.1 Aging

MGD is considered an age-related disease ^{[7, 47]}. Obvious functional and morphologic changes of MG can be detected in asymptomatic populations beyond 35 years-old ^[47]. With aging, the dropout ratio of MG (Meiboscore) raised ^[5], while the MG acinar unit diameters and densities are significantly decreased ^[6]. How aging affects MGD is quite disputable. Previous studies suggested that aging firstly triggered ductal hyperkeratosis and obstruction to result in MG atrophy and dropout ^[3]. However, recent research on MG cadaver specimens from the aged person showed that there is a significant loss of progenitor cells but without ductal hyperkeratosis ^[78]. IVCM detection showed that human aging MG exhibited signs of atrophic but nonobstructive ^[6]. Similarly, proliferative progenitor cells were largely absent in age‐related MGD mouse model ^[79], but hyperkeratinization of MG was failed to detect ^[78-80]. Compared to young mice, the expression of Ki67, which indicates the proliferation activity of cells, was decreased in MG of elder mice ^[80]. Subconjunctival injection of pigment epithelium-derived factor (PEDF), a stem cell proliferation promoter, increased the expression of stem cell markers ΔNp63 and Lrig1 in acinar basal progenitor cells, restored MG acinar area, and improved the TBUT of age-related MGD mice ^[81]. Therefore, a probable mechanism of age-related MGD is the depletion of progenitor cells which leads to MG renewal decompensation, arising subsequent MG atrophy, and dropout ^[19]. Recent in vivo and in vitro models have substantiated this hypothesis that cell senescence induced by high-glucose stimulation markedly induced the depletion of progenitor cells in MG, leading to significant functional acinar dropout ^[82-83]. However, the hyperkeratinization and obstruction of aged MG may attribute to other risk factors ^{[78, 84]}.

The inhibition of PPARγ and FGFR pathways may the mechanisms of age-related MG dropout, for transcriptome analysis of MG showed these two pathways were both significantly suppressed in mice aged 2 years when compared to mice aged 3 months ^[85]. The location of MG acinar is consistent with that of PPARγ ^[80], so significant acinar loss downregulated PPARγ signaling ^[19], intervened with meibocyte differentiation and meibum synthesis ^[84], which could induce ocular desiccative stress and further aggressive the deletion of progenitor and glandular dropout ^{[21, 86]}. FGFR-2 deficiency mouse showed obvious MG dropout and fewer proliferative MG progenitor^[87], while exogenous supplement of fibroblast growth factor (FGF) facilitated the clonal growth of rabbit MG progenitor ^[88].

3.2 Topical anti-glaucoma medications

Chronic use of anti-glaucoma medications (AMs) is a risk factor of MGD. Compared to the normal population, the incidence of MGD among patients who received AMs for more than 1 year is as high as 80% ^[89-90]. The burden of antiglaucoma (BAG), which represents the duration ^[89], frequency ^[91], compliance ^[92], and drug number of AMs ^[93-94], is significantly correlated with the severe degree of MGD ^[91]. Accompanied by worse scores of OSDI and TBUT ^[95], high-BAG population showed increased MG dropout, lower MG acinar density, and thinner TFLL ^{[91, 93, 94]}.

The toxic effects of AMs and the preservative it contained result in MG dropout by directly killing MG acinar cells ^[96-97]. Compared to preservative-free prostaglandin analogue (PGA), preserved PGA induced a severe MG dropout ^[93]. This because BAK, a preservative commonly exists in AMs eyedrops, arose atrophy and death of HMGECs even in the concentrations below the product safety requirements ^[96]. The toxic effects of BAK to MG are magnified when combined with PGA ^{[94, 98]}. Some non-PGA AMs, like pilocarpine and timolol, also inhibited the survival of HMGECs even at a normal dosage ^[99]. BAK- and AMs-induced the downregulation of AKT phosphorylation of HMGECs may the related mechanism ^{[18, 96-97]}.

3.3 Chemotherapy

Chemotherapeutic drugs induced a higher prevalence of MGD, such as TS-1 ^[100] and aromatase inhibitors ^[101], and of which the adverse events of MG induced by anticancer TS-1^® combination capsules are most common. Containing tegafur (FT) and 5-fluorouracil (5-FU), TS-1^® inhibits cellular DNA synthesis and is widely used to treat digestive system cancer ^[102]. Matsumoto first reported that 10 patients all showed foreign body sensation and visual discomfort with significant MG atrophy and dropout after receiving TS-1 chemotherapy for more than 4 months ^[100]. TS-1 chemotherapy reduced MG acinar area in a dose-dependent manner, especially during the period of 3-6 months after chemotherapy ^[102]. FT and 5-FU in tears during TS-1 treatment reached (1.94 ± 0.71) and (0.17 ± 0.11)μ g/mL ^[103]. Chronically exposed to this concentration significantly suppressed the proliferation of various human ocular epithelial cells (cornea, conjunctiva, and retina) ^[104], suggesting that chemotherapeutic drugs accumulated in tears may show extensive toxicity to inhibit the survival of MG acinar cells, arising severe glandular atrophy and dropout in a short time ^[105]. Unfortunately, research involving animal models of systemic chemotherapy tend to pay little attention to the damage of MG or ocular surface caused by chemotherapeutic drugs, which needs to be concerned in the future.

3.4 Radiotherapy

Periocular radiotherapy (PRT), as a typical treatment to periorbital tumors ^[106], is found to cause MG dropout ^[107]. PRT ranged from 30-70 Gy induced MG dropout in a radiation dose-dependent manner [108] with no trails of ductal dilatation or obstruction ^[109]. Even in the lowest radiation dose (≤30 Gy), PRT-treated patients also possessed significant MG dropout, and the scores of OSDI, TBUT, and CFS were all significantly deteriorated ^[107-109]. Besides, among patients only accepted unilateral PRT treatment, their bilateral upper and lower MG both showed severe MG dropout [108]. PRT-induced MG dropout seems to be irreversible, the glandular dropout of patients still in a severe state after discontinued PRT for 6 months ^[109]. Similar to the sebaceous gland and epidermal stem cells, MG also have activated progenitor ^[19], which may make it vulnerable to radiation-induced DNA damage. Histopathological results from patients who had received PRT detected obvious atrophy of MG acinar ^[110], which further indicated that the direct damage of PRT to MG acinar and progenitor cells may the potential pathogenic mechanism.

4. The vicious cycle of MG ductal obstruction and glandular dropout

The role of MG obstruction and MG dropout are interrelated, Meiboscore correlates with meibum expressibility (r = 0.53, P < 0.001) ^[111], compared to Meiboscore 0, patients of Meiboscore 1-3 showed more frequent MG obstruction ^[20]. Due to the risk factors of ductal obstruction and glandular dropout are not exactly identical, they occur in sequence, but together constitute a vicious circle of MGD pathogenesis. MG obstruction induced increased glandular pressure which gradually appeared progenitor cell renewal decompensation, functional acinar atrophy and dropout ^{[1, 3, 112]}. PPARγ is co-located with glandular acinar ^{[19, 80]}, MG dropout made the PPARγ signaling suppressed ^{[22, 25]} and the number of acinar cells differentiate into meibocyte decreased ^{[19, 80]}which resulted in meibum SFA/UFA and lipids-protein abnormalities ^[84], increased hardness and stickiness, but decreased fluidity, causing meibum secretory stagnation ^[34-35], ductal keratinization, and subsequent obstruction ^{[3, 25]}. What’s more, both ductal obstruction and glandular dropout would destruct TFLL structure, inducing ocular desiccative stress and tear evaporation accelerated ^[113-115], which in turn intervene with meibocyte differentiation and progenitor cell proliferation and renewal, aggravating MG obstruction/dropout (Figure 1) ^[21].

Figure 1 The vicious circle of MG ductal obstruction and glandular dropout

Except for timely removal of predisposing factors, early-stage interventions are crucial to break such vicious circle of ductal obstruction and glandular dropout. Though Meibography is often unable to detect MG dropout at an early phase of MG obstruction ^[116], but carrying out treatments like intense pulsed light (IPL) ^[117], warming compress ^[118], intraductal MG probing ^[119], and anti-inflammation is effective for preventing the ocular functional parameters deterioration and secondary acinar dropout induced by long-term MG obstruction. As for cases with significant loss of acinar, PEDF treatment or mechanical intraductal stimulation could activate progenitor to restore the growth and secretion of functional acinar, improving meibum expressibilities and TBUT ^{[81, 119]}

5. Conclusion and outlooks

Comprehensive analysis in the diagnosis and treatment of MGD is necessary since the occurrence of MG obstruction and MG dropout is relatively independent with a certain sequence, which largely depends on the risk factors patients suffered. MG ductal obstruction and glandular dropout interact with each other, long-term obstruction induces acinar cells atrophy and progenitor cells deletion, whereas glandular dropout aggravates meibocyte differentiation and meibum synthesis, increasing the risk of ductal blockage and MGD parameters deterioration. Therefore, timely intervention and removal of predisposing factors are quite important for avoiding falling into the vicious circle of MGD. The construction of HMGECs and MG animal models reveal some reliable molecular basis, PPARγ, FGFR, PI3K-AKT, and NF-κB pathways play an essential role in controlling the proliferation, differentiation, and meibum lipids metabolism of MG which provides potential treatment targets for clinicians. However, the current experimental evidence is still inadequate, the pathogenic mechanisms of some risk factors such as Demodex infestation remain unknown. More sophisticate animal and cellular studies should carry out to clarify the concrete components of meibum lipids with pathogenicity and the process of keratinization of MG ductal epithelial cells. Additionally, effective therapies and potential molecular targets for restoring MG functional acinar also need to be further investigated and validated.

Correction notice

None

Acknowledgement

None

Author Contributions

(Ⅰ) Conception and design: Qi Zhang and Yiqing Li
(Ⅱ) Administrative support: Yehong Zhuo and Yiqing Li
(Ⅲ) Provision of study materials or patients: Jiahui Tang, Zhe Liu, and Caiqing Wu
(Ⅳ) Collection and assembly of data: Siting Wu
(Ⅴ) Data analysis and interpretation: Canying Liu
(Ⅵ) Manuscript writing: All authors
(Ⅶ) Final approval of manuscript: All authors

Fundings

This work was supported by the National Natural Science Foundation of China (82371021, 82201142), the Science Foundation of Guangdong Province (2023A1515012336, 2023A1515010091, 2023A1515030238).

Conflict of Interests

None of the authors has any conflicts of interest to disclose. All authors have declared in the completed the ICMJE uniform disclosure form.

Patient consent for publication

None

Ethical Statement

None

Provenance and Peer Review

This article was a standard submission to our journal. The article has undergone peer review with our anonymous review system.

Data Sharing Statement

None

Open Access Statement

This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

1、Obata H. Anatomy and histopathology of human meibomian gland. Cornea. 2002, 21(7 Suppl): S70-S74. DOI: 10.1097/01.ico.0000263122.45898.09.

2、Butovich IA. Meibomian glands, meibum, and meibogenesis. Exp Eye Res. 2017, 163: 2-16. DOI: 10.1016/j.exer.2017.06.020.

3、Knop E, Knop N, Millar T, et al. The international workshop on meibomian gland dysfunction: report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland. Invest Ophthalmol Vis Sci. 2011, 52(4): 1938-1978. DOI: 10.1167/iovs.10-6997c.

4、Baudouin C, Messmer EM, Aragona P, et al. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunction. Br J Ophthalmol. 2016, 100(3): 300-306. DOI: 10.1136/bjophthalmol-2015-307415.

5、Arita R, Itoh K, Inoue K, et al. Noncontact infrared meibography to document age-related changes of the meibomian glands in a normal population. Ophthalmology. 2008, 115(5): 911-915. DOI: 10.1016/j.ophtha.2007.06.031.

6、Villani E, Canton V, Magnani F, et al. The aging Meibomian gland: an in vivo confocal study. Invest Ophthalmol Vis Sci. 2013, 54(7): 4735-4740. DOI: 10.1167/iovs.13-11914.

7、Viso E, Rodríguez-Ares MT, Abelenda D, et al. Prevalence of asymptomatic and symptomatic meibomian gland dysfunction in the general population of Spain. Invest Ophthalmol Vis Sci, 2012, 53(6): 2601-2606. DOI: 10.1167/iovs.11-9228.

8、Uchino M, Dogru M, Yagi Y, et al. The features of dry eye disease in a Japanese elderly population. Optom Vis Sci. 2006, 83(11): 797-802. DOI: 10.1097/01.opx.0000232814.39651.fa.

9、Moreno I, Verma S, Gesteira TF, et al. Recent advances in age-related meibomian gland dysfunction (ARMGD). Ocul Surf. 2023, 30: 298-306. DOI: 10.1016/j.jtos.2023.11.003.

10、Asiedu K, Dzasimatu S, Kyei S. Impact of meibomian gland dysfunction on quality of life and mental health in a clinical sample in Ghana: a cross-sectional study. BMJ Open. 2022, 12(9): e061758. DOI: 10.1136/bmjopen-2022-061758.

11、Chhadva P, Goldhardt R, Galor A. Meibomian gland disease: the role of gland dysfunction in dry eye disease. Ophthalmology. 2017, 124(11S): S20-S26. DOI: 10.1016/j.ophtha.2017.05.031.

12、Jester JV, Parfitt GJ, Brown DJ. Meibomian gland dysfunction: hyperkeratinization or atrophy. BMC Ophthalmol. 2015, 15(Suppl 1): 156. DOI: 10.1186/s12886-015-0132-x.

13、Xu KK, Huang YK, Liu X, et al. Organotypic culture of mouse meibomian gland: a novel model to study meibomian gland dysfunction in vitro. Invest Ophthalmol Vis Sci. 2020, 61(4): 30. DOI: 10.1167/iovs.61.4.30.

14、Krenzer KL, Dana MR, Ullman MD, et al. Effect of androgen deficiency on the human meibomian gland and ocular surface. J Clin Endocrinol Metab. 2000, 85(12): 4874-4882. DOI: 10.1210/jcem.85.12.7072.

15、Golebiowski%20B%2C%20Badarudin%20N%2C%20Eden%20J%2C%20et%20al.%20Does%20endogenous%20serum%20oestrogen%20play%20a%20role%20in%20meibomian%20gland%20dysfunction%20in%20postmenopausal%20women%20with%20dry%20eye%3F%20Br%20J%20Ophthalmol.%202017%2C%20101(2)%3A%20218-222.%20DOI%3A%2010.1136%2Fbjophthalmol-2016-308473.

16、Bu J, Zhang M, Wu Y, et al. High-fat diet induces inflammation of meibomian gland. Invest Ophthalmol Vis Sci. 2021, 62(10): 13. DOI: 10.1167/iovs.62.10.13.

17、Cermak%20JM%2C%20Krenzer%20KL%2C%20Sullivan%20RM%2C%20et%20al.%20Is%20complete%20androgen%20insensitivity%20syndrome%20associated%20with%20alterations%20in%20the%20meibomian%20gland%20and%20ocular%20surface%3F%20Cornea.%202003%2C%2022(6)%3A%20516-521.%20DOI%3A%2010.1097%2F00003226-200308000-00006.%20

18、Wang J, Liu Y, Kam WR, et al. Toxicity of the cosmetic preservatives parabens, phenoxyethanol and chlorphenesin on human meibomian gland epithelial cells. Exp Eye Res. 2020, 196: 108057. DOI: 10.1016/j.exer.2020.108057.

19、Nien CJ, Massei S, Lin G, et al. Effects of age and dysfunction on human meibomian glands. Arch Ophthalmol. 2011, 129(4): 462-469. DOI: 10.1001/archophthalmol.2011.69.

20、Adil MY, Xiao J, Olafsson J, et al. Meibomian gland morphology is a sensitive early indicator of meibomian gland dysfunction. Am J Ophthalmol. 2019, 200: 16-25. DOI: 10.1016/j.ajo.2018.12.006.

21、Suhalim JL, Parfitt GJ, Xie Y, et al. Effect of desiccating stress on mouse meibomian gland function. Ocul Surf. 2014, 12(1): 59-68. DOI: 10.1016/j.jtos.2013.08.002.

22、Jester JV, Potma E, Brown DJ. PPARγ regulates mouse meibocyte differentiation and lipid synthesis. Ocul Surf. 2016, 14(4): 484-494. DOI: 10.1016/j.jtos.2016.08.001.

23、Qazi Y, Kheirkhah A, Blackie C, et al. Clinically relevant immune-cellular metrics of inflammation in meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2018, 59(15): 6111-6123. DOI: 10.1167/iovs.18-25571.

24、Reyes NJ, Yu C, Mathew R, et al. Neutrophils cause obstruction of eyelid sebaceous glands in inflammatory eye disease in mice. Sci Transl Med. 2018, 10(451): eaas9164. DOI: 10.1126/scitranslmed.aas9164.

25、Bu J, Wu Y, Cai X, et al. Hyperlipidemia induces meibomian gland dysfunction. Ocul Surf. 2019, 17(4): 777-786. DOI: 10.1016/j.jtos.2019.06.002.

26、Schr%C3%B6der%20A%2C%20Abrar%20DB%2C%20Hampel%20U%2C%20et%20al.%20In%20vitro%20effects%20of%20sex%20hormones%20in%20human%20meibomian%20gland%20epithelial%20cells.%20Exp%20Eye%20Res.%202016%2C%20151%3A%20190-202.%20DOI%3A%2010.1016%2Fj.exer.2016.08.009.

27、Butovich IA, Bhat N, Wojtowicz JC. Comparative transcriptomic and lipidomic analyses of human male and female meibomian glands reveal common signature genes of meibogenesis. Int J Mol Sci. 2019, 20(18): 4539. DOI: 10.3390/ijms20184539.

28、Khandelwal P, Liu S, Sullivan DA. Androgen regulation of gene expression in human meibomian gland and conjunctival epithelial cells. Mol Vis. 2012, 18: 1055-1067.

29、Schirra F, Richards SM, Liu M, et al. Androgen regulation of lipogenic pathways in the mouse meibomian gland. Exp Eye Res. 2006, 83(2): 291-296. DOI: 10.1016/j.exer.2005.11.026.

30、Suzuki T, Schirra F, Richards SM, et al. Estrogen and progesterone control of gene expression in the mouse meibomian gland. Invest Ophthalmol Vis Sci. 2008, 49(5): 1797-1808. DOI: 10.1167/iovs.07-1458.

31、Suzuki T, Fujiwara S, Kinoshita S, et al. Cyclic change of fatty acid composition in meibum during the menstrual cycle. Invest Ophthalmol Vis Sci. 2019, 60(5): 1724-1733. DOI: 10.1167/iovs.18-26390.

32、Inaba T, Tanaka Y, Tamaki S, et al. Compensatory increases in tear volume and mucin levels associated with meibomian gland dysfunction caused by stearoyl-CoA desaturase-1 deficiency. Sci Rep. 2018, 8(1): 3358. DOI: 10.1038/s41598-018-21542-3.

33、Sassa T, Tadaki M, Kiyonari H, et al. Very long-chain tear film lipids produced by fatty acid elongase ELOVL1 prevent dry eye disease in mice. FASEB J. 2018, 32(6): 2966-2978. DOI: 10.1096/fj.201700947R.

34、Borchman D, Foulks GN, Yappert MC, et al. Human meibum lipid conformation and thermodynamic changes with meibomian-gland dysfunction. Invest Ophthalmol Vis Sci. 2011, 52(6): 3805-3817. DOI: 10.1167/iovs.10-6514.

35、 Borchman D, Ramasubramanian A. Human meibum chain branching variability with age, gender and meibomian gland dysfunction. Ocul Surf. 2019, 17(2): 327-335. DOI: 10.1016/j.jtos.2018.12.005.

36、Kim SW, Xie Y, Nguyen PQ, et al. PPARγ regulates meibocyte differentiation and lipid synthesis of cultured human meibomian gland epithelial cells (hMGEC). Ocul Surf. 2018, 16(4): 463-469. DOI: 10.1016/j.jtos.2018.07.004.

37、Kim SW, Brown DJ, Jester JV. Transcriptome analysis after PPARγ activation in human meibomian gland epithelial cells (hMGEC). Ocul Surf. 2019, 17(4): 809-816. DOI: 10.1016/j.jtos.2019.02.003.

38、Gidfar S, Afsharkhamseh N, Sanjari S, et al. Notch signaling in meibomian gland epithelial cell differentiation. Invest Ophthalmol Vis Sci. 2016, 57(3): 859-865. DOI: 10.1167/iovs.15-18319.

39、Ding J, Sullivan DA. The effects of insulin-like growth factor 1 and growth hormone on human meibomian gland epithelial cells. JAMA Ophthalmol. 2014, 132(5): 593-599. DOI: 10.1001/jamaophthalmol.2013.8295.

40、Braun RJ, King-Smith PE, Begley CG, et al. Dynamics and function of the tear film in relation to the blink cycle. Prog Retin Eye Res. 2015, 45: 132-164. DOI: 10.1016/j.preteyeres.2014.11.001.

41、Wang MTM, Tien L, Han A, et al. Impact of blinking on ocular surface and tear film parameters. Ocul Surf. 2018, 16(4): 424-429. DOI: 10.1016/j.jtos.2018.06.001.

42、Nosch DS, Foppa C, Tóth M, et al. Blink animation software to improve blinking and dry eye symptoms. Optom Vis Sci. 2015, 92(9): e310-e315. DOI: 10.1097/OPX.0000000000000654.

43、Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017, 15(3): 438-510. DOI: 10.1016/j.jtos.2017.05.011.

44、Wan T, Jin X, Lin L, et al. Incomplete blinking may attribute to the development of meibomian gland dysfunction. Curr Eye Res. 2016, 41(2): 179-185. DOI: 10.3109/02713683.2015.1007211.

45、Park J, Baek S. Dry eye syndrome in thyroid eye disease patients: the role of increased incomplete blinking and Meibomian gland loss. Acta Ophthalmol. 2019, 97(5): e800-e806. DOI: 10.1111/aos.14000.

46、Fan F, Li X, Li K, et al. To find out the relationship between levels of glycosylated hemoglobin with meibomian gland dysfunction in patients with type 2 diabetes. Ther Clin Risk Manag. 2021, 17: 797-807. DOI: 10.2147/TCRM.S324423.

47、Amano S, Inoue K. Clinic-based study on meibomian gland dysfunction in Japan. Invest Ophthalmol Vis Sci. 2017, 58(2): 1283-1287. DOI: 10.1167/iovs.16-21374.

48、raig JP, Lim J, Han A, et al. Ethnic differences between the Asian and Caucasian ocular surface: a co-located adult migrant population cohort study. Ocul Surf. 2019, 17(1): 83-88. DOI: 10.1016/j.jtos.2018.09.005.

49、Jeong S, Lemke BN, Dortzbach RK, et al. The Asian upper eyelid: an anatomical study with comparison to the Caucasian eyelid. Arch Ophthalmol. 1999, 117(7): 907-912. DOI: 10.1001/archopht.117.7.907.

50、Cho M, Glavas IP. Anatomic properties of the upper eyelid in Asian Americans. Dermatol Surg. 2009, 35(11): 1736-1740. DOI: 10.1111/j.1524-4725.2009.01285.x.

51、Craig JP, Wang MTM, Kim D, et al. Exploring the predisposition of the Asian eye to development of dry eye. Ocul Surf. 2016, 14(3): 385-392. DOI: 10.1016/j.jtos.2016.03.002.

52、Kim JS, Wang MTM, Craig JP. Exploring the Asian ethnic predisposition to dry eye disease in a pediatric population. Ocul Surf. 2019, 17(1): 70-77. DOI: 10.1016/j.jtos.2018.09.003.

53、Bailey RL, Gahche JJ, Miller PE, et al. Why US adults use dietary supplements. JAMA Intern Med. 2013, 173(5): 355-361. DOI: 10.1001/jamainternmed.2013.2299.

54、Kantor ED, Rehm CD, Du M, et al. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016, 316(14): 1464-1474. DOI: 10.1001/jama.2016.14403.

55、Gong%20W%2C%20Liu%20A%2C%20Yao%20Y%2C%20et%20al.%20Nutrient%20supplement%20use%20among%20the%20Chinese%20population%3A%20a%20cross-sectional%20study%20of%20the%202010%E2%81%BB2012%20China%20nutrition%20and%20health%20surveillance.%20Nutrients.%202018%2C%2010(11)%3A%201733.%20DOI%3A%2010.3390%2Fnu10111733.%20

56、Ziemanski JF, Wolters LR, Jones-Jordan L, et al. Relation between dietary essential fatty acid intake and dry eye disease and meibomian gland dysfunction in postmenopausal women. Am J Ophthalmol. 2018, 189: 29-40. DOI: 10.1016/j.ajo.2018.01.004.

57、Macsai MS. The role of omega-3 dietary supplementation in blepharitis and meibomian gland dysfunction (an AOS thesis). Trans Am Ophthalmol Soc. 2008, 106: 336-356.

58、Liu Y, Kam WR, Sullivan DA. Influence of omega 3 and 6 fatty acids on human meibomian gland epithelial cells. Cornea. 2016, 35(8): 1122-1126. DOI: 10.1097/ICO.0000000000000874.

59、Ole%C3%B1ik%20A%2C%20Jim%C3%A9nez-Alfaro%20I%2C%20Alejandre-Alba%20N%2C%20et%20al.%20A%20randomized%2C%20double-masked%20study%20to%20evaluate%20the%20effect%20of%20omega-3%20fatty%20acids%20supplementation%20in%20meibomian%20gland%20dysfunction.%20Clin%20Interv%20Aging.%202013%2C%208%3A%201133-1138.%20DOI%3A%2010.2147%2FCIA.S48955.%20

60、Hampel U, Krüger M, Kunnen C, et al. In vitro effects of docosahexaenoic and eicosapentaenoic acid on human meibomian gland epithelial cells. Exp Eye Res. 2015, 140: 139-148. DOI: 10.1016/j.exer.2015.08.024.

61、Arita R, Itoh K, Inoue K, et al. Contact lens wear is associated with decrease of meibomian glands. Ophthalmology. 2009, 116(3): 379-384. DOI: 10.1016/j.ophtha.2008.10.012.

62、U%C3%A7akhan%20%C3%96%2C%20Arslanturk-Eren%20M.%20The%20role%20of%20soft%20contact%20lens%20wear%20on%20meibomian%20gland%20morphology%20and%20function.%20Eye%20Contact%20Lens.%202019%2C%2045(5)%3A%20292-300.%20DOI%3A%2010.1097%2FICL.0000000000000572.%20

63、Henriquez AS, Korb DR. Meibomian glands and contact lens wear. Br J Ophthalmol. 1981, 65(2): 108-111. DOI: 10.1136/bjo.65.2.108.

64、Villani E, Ceresara G, Beretta S, et al. In vivo confocal microscopy of meibomian glands in contact lens wearers. Invest Ophthalmol Vis Sci. 2011, 52(8): 5215-5219. DOI: 10.1167/iovs.11-7427.

65、Gad A, Vingrys AJ, Wong CY, et al. Tear film inflammatory cytokine upregulation in contact lens discomfort. Ocul Surf. 2019, 17(1): 89-97. DOI: 10.1016/j.jtos.2018.10.004.

66、Schultz CL, Kunert KS. Interleukin-6 levels in tears of contact lens wearers. J Interferon Cytokine Res. 2000, 20(3): 309-310. DOI: 10.1089/107999000312441.

67、Alghamdi W, Markoulli M, Papas E. The relationship between tear film MMP-9 and meibomian gland changes during soft contact lens wear. Cont Lens Anterior Eye. 2020, 43(2): 154-158. DOI: 10.1016/j.clae.2019.07.007.

68、Alghamdi WM, Markoulli M, Holden BA, et al. Impact of duration of contact lens wear on the structure and function of the meibomian glands. Ophthalmic Physiol Opt. 2016, 36(2): 120-131. DOI: 10.1111/opo.12278.

69、Gutgesell VJ, Stern GA, Hood CI. Histopathology of meibomian gland dysfunction. Am J Ophthalmol. 1982, 94(3): 383-387. DOI: 10.1016/0002-9394(82)90365-8.

70、English FP, Nutting WB. Demodicosis of ophthalmic concern. Am J Ophthalmol. 1981, 91(3): 362-372. DOI: 10.1016/0002-9394(81)90291-9.

71、Liang L, Liu Y, Ding X, et al. Significant correlation between meibomian gland dysfunction and keratitis in young patients with Demodex brevis infestation. Br J Ophthalmol. 2018, 102(8): 1098-1102. DOI: 10.1136/bjophthalmol-2017-310302.

72、Lee SH, Chun YS, Kim JH, et al. The relationship between demodex and ocular discomfort. Invest Ophthalmol Vis Sci. 2010, 51(6): 2906-2911. DOI: 10.1167/iovs.09-4850.

73、Zhu M, Cheng C, Yi H, et al. Quantitative analysis of the bacteria in blepharitis with demodex infestation. Front Microbiol. 2018, 9: 1719. DOI: 10.3389/fmicb.2018.01719.

74、Lacey N, Delaney S, Kavanagh K, et al. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007, 157(3): 474-481. DOI: 10.1111/j.1365-2133.2007.08028.x.

75、Rabensteiner DF, Aminfar H, Boldin I, et al. Demodex mite infestation and its associations with tear film and ocular surface parameters in patients with ocular discomfort. Am J Ophthalmol. 2019, 204: 7-12. DOI: 10.1016/j.ajo.2019.03.007.

76、Liang L, Ding X, Tseng SCG. High prevalence of demodex brevis infestation in chalazia. Am J Ophthalmol. 2014, 157(2): 342-348.e1. DOI: 10.1016/j.ajo.2013.09.031.

77、Randon M, Liang H, El Hamdaoui M, et al. In vivo confocal microscopy as a novel and reliable tool for the diagnosis of Demodex eyelid infestation. Br J Ophthalmol. 2015, 99(3): 336-341. DOI: 10.1136/bjophthalmol-2014-305671.

78、Reneker LW, Irlmeier RT, Shui YB, et al. Histopathology and selective biomarker expression in human meibomian glands. Br J Ophthalmol. 2020, 104(7): 999-1004. DOI: 10.1136/bjophthalmol-2019-314466.

79、Parfitt GJ, Xie Y, Geyfman M, et al. Absence of ductal hyper-keratinization in mouse age-related meibomian gland dysfunction (ARMGD). Aging. 2013, 5(11): 825-834. DOI: 10.18632/aging.100615.

80、Nien CJ, Paugh JR, Massei S, et al. Age-related changes in the meibomian gland. Exp Eye Res. 2009, 89(6): 1021-1027. DOI: 10.1016/j.exer.2009.08.013.

81、Fan NW, Ho TC, Lin EH, et al. Pigment epithelium-derived factor peptide reverses mouse age-related meibomian gland atrophy. Exp Eye Res. 2019, 185: 107678. DOI: 10.1016/j.exer.2019.05.018.

82、Guo Y, Zhang H, Zhao Z, et al. Hyperglycemia induces meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2022, 63(1): 30. DOI: 10.1167/iovs.63.1.30.

83、Ding J, Liu Y, Sullivan DA. Effects of insulin and high glucose on human meibomian gland epithelial cells. Invest Ophthalmol Vis Sci. 2015, 56(13): 7814-7820. DOI: 10.1167/iovs.15-18049.

84、Sullivan BD, Evans JE, Dana MR, et al. Influence of aging on the polar and neutral lipid profiles in human meibomian gland secretions. Arch Ophthalmol. 2006, 124(9): 1286-1292. DOI: 10.1001/archopht.124.9.1286.

85、Parfitt GJ, Brown DJ, Jester JV. Transcriptome analysis of aging mouse meibomian glands. Mol Vis. 2016, 22: 518-527.

86、Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology. 1993, 100(3): 347-351. DOI: 10.1016/s0161-6420(93)31643-x.

87、Reneker LW, Wang L, Irlmeier RT, et al. Fibroblast growth factor receptor 2 (FGFR2) is required for meibomian gland homeostasis in the adult mouse. Invest Ophthalmol Vis Sci. 2017, 58(5): 2638-2646. DOI: 10.1167/iovs.16-21204.

88、Maskin SL, Tseng SC. Clonal growth and differentiation of rabbit meibomian gland epithelium in serum-free culture: differential modulation by EGF and FGF. Invest Ophthalmol Vis Sci. 1992, 33(1): 205-217.

89、Ghosh S, O’Hare F, Lamoureux E, et al. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012, 40(7): 675-681. DOI: 10.1111/j.1442-9071.2012.02781.x.

90、Uzunosmanoglu E, Mocan MC, Kocabeyoglu S, et al. Meibomian gland dysfunction in patients receiving long-term glaucoma medications. Cornea. 2016, 35(8): 1112-1116. DOI: 10.1097/ICO.0000000000000838.

91、Cho WH, Lai IC, Fang PC, et al. Meibomian gland performance in glaucomatous patients with long-term instillation of IOP-lowering medications. J Glaucoma. 2018, 27(2): 176-183. DOI: 10.1097/IJG.0000000000000841.

92、Lee TH, Sung MS, Heo H, et al. Association between meibomian gland dysfunction and compliance of topical prostaglandin analogs in patients with normal tension glaucoma. PLoS One. 2018, 13(1): e0191398. DOI: 10.1371/journal.pone.0191398.

93、Agnifili L, Fasanella V, Costagliola C, et al. In vivo confocal microscopy of meibomian glands in glaucoma. Br J Ophthalmol. 2013, 97(3): 343-349. DOI: 10.1136/bjophthalmol-2012-302597.

94、Agnifili L, Mastropasqua R, Fasanella V, et al. Meibomian gland features and conjunctival goblet cell density in glaucomatous patients controlled with prostaglandin/timolol fixed combinations: a case control, cross-sectional study. J Glaucoma. 2018, 27(4): 364-370. DOI: 10.1097/IJG.0000000000000899.

95、Mathews PM, Ramulu PY, Friedman DS, et al. Evaluation of ocular surface disease in patients with glaucoma. Ophthalmology. 2013, 120(11): 2241-2248. DOI: 10.1016/j.ophtha.2013.03.045.

96、Chen X, Sullivan DA, Sullivan AG, et al. Toxicity of cosmetic preservatives on human ocular surface and adnexal cells. Exp Eye Res. 2018, 170: 188-197. DOI: 10.1016/j.exer.2018.02.020.

97、Kam%20WR%2C%20Liu%20Y%2C%20Ding%20J%2C%20et%20al.%20Do%20cyclosporine%20A%2C%20an%20IL-1%20receptor%20antagonist%2C%20uridine%20triphosphate%2C%20rebamipide%2C%20and%2For%20bimatoprost%20regulate%20human%20meibomian%20gland%20epithelial%20cells%3F%20Invest%20Ophthalmol%20Vis%20Sci.%202016%2C%2057(10)%3A%204287-4294.%20DOI%3A%2010.1167%2Fiovs.16-19937.%20

98、Rath%20A%2C%20Eichhorn%20M%2C%20Tr%C3%A4ger%20K%2C%20et%20al.%20In%20vitro%20effects%20of%20benzalkonium%20chloride%20and%20prostaglandins%20on%20human%20meibomian%20gland%20epithelial%20cells.%20Ann%20Anat.%202019%2C%20222%3A%20129-138.%20DOI%3A%2010.1016%2Fj.aanat.2018.12.003.%20

99、Zhang Y, Kam WR, Liu Y, et al. Influence of pilocarpine and timolol on human meibomian gland epithelial cells. Cornea. 2017, 36(6): 719-724. DOI: 10.1097/ICO.0000000000001181.

100、Matsumoto Y, Dogru M, Sato EA, et al. S-1 induces meibomian gland dysfunction. Ophthalmology. 2010, 117(6): 1275.e4-1275.e7. DOI: 10.1016/j.ophtha.2010.01.048.

101、Chatziralli I, Sergentanis T, Zagouri F, et al. Ocular surface disease in breast cancer patients using aromatase inhibitors. Breast J. 2016, 22(5): 561-563. DOI: 10.1111/tbj.12633.

102、Ohtomo K, Arita R, Shirakawa R, et al. Quantitative analysis of changes to meibomian gland morphology due to S-1 chemotherapy. Transl Vis Sci Technol. 2018, 7(6): 37. DOI: 10.1167/tvst.7.6.37.

103、Akune Y, Yamada M, Shigeyasu C. Determination of 5-fluorouracil and tegafur in tear fluid of patients treated with oral fluoropyrimidine anticancer agent, S-1. Jpn J Ophthalmol. 2018, 62(4): 432-437. DOI: 10.1007/s10384-018-0603-8.

104、Huhtala%20A%2C%20R%C3%B6nkk%C3%B6%20S%2C%20Ter%C3%A4svirta%20M%2C%20et%20al.%20The%20effects%20of%205-fluorouracil%20on%20ocular%20tissues%20in%20vitro%20and%20in%20vivo%20after%20controlled%20release%20from%20a%20multifunctional%20implant.%20Invest%20Ophthalmol%20Vis%20Sci.%202009%2C%2050(5)%3A%202216-2223.%20DOI%3A%2010.1167%2Fiovs.08-3016.%20

105、Eom Y, Baek S, Kim HM, et al. Meibomian gland dysfunction in patients with chemotherapy-induced lacrimal drainage obstruction. Cornea. 2017, 36(5): 572-577. DOI: 10.1097/ICO.0000000000001172.

106、Yin VT, Merritt HA, Sniegowski M, et al. Eyelid and ocular surface carcinoma: diagnosis and management. Clin Dermatol. 2015, 33(2): 159-169. DOI: 10.1016/j.clindermatol.2014.10.008.

107、Woo YJ, Ko J, Ji YW, et al. Meibomian gland dysfunction associated with periocular radiotherapy. Cornea. 2017, 36(12): 1486-1491. DOI: 10.1097/ICO.0000000000001377.

108、Chen D, Liu X, Li Y, et al. Impact of unilateral orbital radiotherapy on the structure and function of bilateral human meibomian gland. J Ophthalmol. 2018, 2018: 9308649. DOI: 10.1155/2018/9308649.

109、Kim SE, Yang HJ, Yang SW. Effects of radiation therapy on the meibomian glands and dry eye in patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma. BMC Ophthalmol. 2020, 20(1): 24. DOI: 10.1186/s12886-019-1301-0.

110、Karp LA, Streeten BW, Cogan DG. Radiation-induced atrophy of the Meibomian gland. Arch Ophthalmol. 1979, 97(2): 303-305. DOI: 10.1001/archopht.1979.01020010155013.

111、Xiao J, Adil MY, Olafsson J, et al. Diagnostic test efficacy of meibomian gland morphology and function. Sci Rep. 2019, 9(1): 17345. DOI: 10.1038/s41598-019-54013-4.

112、Miyake H, Oda T, Katsuta O, et al. Meibomian gland dysfunction model in hairless mice fed a special diet with limited lipid content. Invest Ophthalmol Vis Sci. 2016, 57(7): 3268-3275. DOI: 10.1167/iovs.16-19227.

113、Goto E, Endo K, Suzuki A, et al. Tear evaporation dynamics in normal subjects and subjects with obstructive meibomian gland dysfunction. Invest Ophthalmol Vis Sci. 2003, 44(2): 533-539. DOI: 10.1167/iovs.02-0170.

114、Eom Y, Lee JS, Kang SY, et al. Correlation between quantitative measurements of tear film lipid layer thickness and meibomian gland loss in patients with obstructive meibomian gland dysfunction and normal controls. Am J Ophthalmol. 2013, 155(6): 1104-1110.e2. DOI: 10.1016/j.ajo.2013.01.008.

115、Menzies%20KL%2C%20Srinivasan%20S%2C%20Prokopich%20CL%2C%20et%20al.%20Infrared%20imaging%20of%20meibomian%20glands%20and%20evaluation%20of%20the%20lipid%20layer%20in%20Sj%C3%B6gren%E2%80%99s%20syndrome%20patients%20and%20nondry%20eye%20controls.%20Invest%20Ophthalmol%20Vis%20Sci.%202015%2C%2056(2)%3A%20836-841.%20DOI%3A%2010.1167%2Fiovs.14-13864.%20

116、Eom%20Y%2C%20Han%20JY%2C%20Kang%20B%2C%20et%20al.%20Meibomian%20Glands%20and%20Ocular%20Surface%20Changes%20After%20Closure%20of%20Meibomian%20Gland%20Orifices%20in%20Rabbits.%20Cornea.%202018%2C%2037(2)%3A218-226.%20DOI%3A%2010.1097%2FICO.0000000000001460.%C2%A0

117、Arita R, Fukuoka S, Morishige N. Therapeutic efficacy of intense pulsed light in patients with refractory meibomian gland dysfunction. Ocul Surf, 2019, 17(1): 104-110. DOI: 10.1016/j.jtos.2018.11.004.

118、Song P, Sun Z, Ren S, et al. Preoperative management of MGD alleviates the aggravation of MGD and dry eye induced by cataract surgery: a prospective, randomized clinical trial. Biomed Res Int. 2019, 2019: 2737968. DOI: 10.1155/2019/2737968.

119、Maskin SL, Testa WR. Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction. Br J Ophthalmol. 2018, 102(1): 59-68. DOI: 10.1136/bjophthalmol-2016-310097.

1、This work was supported by the National Natural Science Foundation of China (82371021, 82201142), the Science Foundation of Guangdong Province (2023A1515012336, 2023A1515010091, 2023A1515030238).()